Literature DB >> 27169329

Molecular diagnosis and molecular profiling to detect treatment-resistant ovarian cancer.

Diana P English1, Gulden Menderes2, Jonathan Black1, Carlton L Schwab2, Alessandro D Santin2.   

Abstract

INTRODUCTION: Epithelial ovarian cancer remains the gynecologic tumor with the highest rate of recurrence after initial optimal cytoreductive surgery followed by adjuvant chemotherapy. Unfortunately, with the development of recurrent ovarian cancer often comes the discovery of chemo-resistant disease. The absence of improvement in long term survival, notwithstanding the use of newer agents as is seen in other cancers, emphasizes the need for improved understanding of the processes that lead to chemo-resistant disease. AREAS COVERED: This review will cover the following topics: 1. Molecular and cellular mechanisms in platinum and paclitaxel resistance 2. Other molecular mediators of chemo-resistance 3. Expression of stem cell markers in ovarian cancer and relationship to chemo-resistance 4. MicroRNA and long non-coding RNA expression in chemo-resistant ovarian cancer 5. Determination of chromosomal aberrations as markers of chemo-resistance 6. Molecular profiling in chemo-resistant disease. A standard MEDLINE search was performed using the key words; ovarian cancer, chemo-resistant disease, molecular profiling, cancer stem cells and chemotherapy. Expert Commentary: Over the next few years the challenge remains to precisely determine the mechanisms responsible for the onset and maintenance of chemo-resistance and to effectively target these mechanisms.

Entities:  

Keywords:  Ovarian cancer; cancer stem cells; chemo-resistant disease; chemotherapy; molecular profiling

Mesh:

Substances:

Year:  2016        PMID: 27169329     DOI: 10.1080/14737159.2016.1188692

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  5 in total

1.  Novel Chimeric Poxvirus CF17 Improves Survival in a Murine Model of Intraperitoneal Ovarian Cancer Metastasis.

Authors:  Mohamed Hammad; Yvonne Cornejo; Linda Flores; Caitlyn Hyde; Hoi Wa Ngai; Min Li; Thanh H Dellinger; Jianming Lu; Nanhai G Chen; Rachael Mooney; Karen S Aboody; Yuman Fong
Journal:  Mol Ther Oncolytics       Date:  2020-10-10       Impact factor: 7.200

2.  Loss of TAB3 expression by shRNA exhibits suppressive bioactivity and increased chemical sensitivity of ovarian cancer cell lines via the NF-κB pathway.

Authors:  Yannan Chen; Xia Wang; Chengwei Duan; Jie Chen; Ming Su; Yunfeng Jin; Yan Deng; Di Wang; Caiwen Chen; Linsen Zhou; Jialin Cheng; Wei Wang; Qinghua Xi
Journal:  Cell Prolif       Date:  2016-09-21       Impact factor: 6.831

3.  OvAd1, a Novel, Potent, and Selective Chimeric Oncolytic Virus Developed for Ovarian Cancer by 3D-Directed Evolution.

Authors:  Irene Kuhn; Maxine Bauzon; Nicola Green; Len Seymour; Kerry Fisher; Terry Hermiston
Journal:  Mol Ther Oncolytics       Date:  2016-12-14       Impact factor: 7.200

4.  A Lab-on-a-Chip Device Integrated DNA Extraction and Solid Phase PCR Array for the Genotyping of High-Risk HPV in Clinical Samples.

Authors:  Cancan Zhu; Anzhong Hu; Junsheng Cui; Ke Yang; Xinchao Zhu; Yong Liu; Guoqing Deng; Ling Zhu
Journal:  Micromachines (Basel)       Date:  2019-08-15       Impact factor: 2.891

5.  High expression of RIPK2 is associated with Taxol resistance in serous ovarian cancer.

Authors:  Yuqing Shen; Hui Lin; Kelie Chen; Wanzhong Ge; Dajing Xia; Yihua Wu; Weiguo Lu
Journal:  J Ovarian Res       Date:  2022-04-27       Impact factor: 5.506

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.